Navigation Links
ALK Product Portfolio Not Affected by Glass Delamination Recall
Date:7/23/2013

ROUND ROCK, Texas, July 23, 2013 /PRNewswire/ -- A recent recall by a major manufacturer of Albumin Saline with Phenol (ABS) and Normal Saline with Phenol (NSP) products due to glass delamination has led to inaccurate claims of an "industry wide" recall of injectable pharmaceutical products in the allergy industry. ALK, a leading company focusing on allergy treatment, is pleased to announce that the entire ALK portfolio of products is not affected by this recall.

ABS and NSP are used as diluents with allergenic extracts to create customized immunotherapy treatments for patients. Various companies supply glass products to the pharmaceutical industry, but only one supplier has experienced glass delamination issues at this time. According to the Food and Drug Administration, glass delamination occurs when small volume vials shed thin, flexible glass fragments into the solution. http://1.usa.gov/15GEd1i  

"ALK does not use the glass products from the manufacturer that has experienced the problem of glass delamination," said Jorge Alderete, ALK Senior Vice President of Commercial Operations. "This recall is isolated to a single glass vendor, and is not what ALK would consider to be an 'Industry Wide' issue.  ALK takes this issue very seriously, and after thoroughly researching the issue through our scientific, quality, and regulatory departments, ALK is pleased to report our vials do not exhibit glass delamination and ALK has sufficient product available to meet patient needs."

About ALK
ALK is a research driven, global pharmaceutical company focusing on allergy treatment, prevention and diagnosis. As the world leader in allergy immunotherapy, a treatment given to increase immunity to substances causing allergic symptoms, ALK is devoted to improving the quality of life for people with allergies by creating products that treat the cause of allergies. ALK and the Asthma and Allergy Foundation of America have partnered to create a unique online resource on allergy immunotherapy for patients:  www.fightthecauseofallergy.org ALK is also committed to supporting the business of allergy by providing diagnostic tools, automation software and customized business, technical and clinical consulting services.

Media Contact
Staci Young
ALK
512.990.6008
staci.young@alk.net


'/>"/>
SOURCE ALK
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. A*STARs SIMTech and NUS Faculty of Engineering Launch Joint Labs to Boost Manufacturing Productivity
2. Instrumentation Laboratory Awarded Premier Healthcare Alliance Contract For Hemostasis Product Line
3. Educating Key Stakeholder to Support a Successful Diabetes Product Launch
4. Chronic Obstructive Pulmonary Disease (COPD) Market to 2019 - Highly-Priced New Combination Products Forecast to Capture Significant Market Share and Drive Growth
5. Global Decubitus Ulcer Treatment Products Industry
6. SAM Medical Products Selected a Winner in the 34th Annual Telly Awards
7. Abuse-Deterrent Formulations of Purdues OxyContin and Endo Pharmaceuticals Opana ER Have Not Increased PCPs Comfort When Prescribing These Products for Chronic Pain
8. Products From Eight Health-IT Vendors First to Receive Certification Under New Program Launched by IHE USA and ICSA Labs
9. After Reviewing Brief Product Profiles, Surveyed Physicians Believe that Likely Candidates for Late-Phase Chronic Kidney Disease Products from AbbVie, Mitsubishi Tanabe, Eli Lilly, Concert, Fibrogen and Pfizer are Typically Stage 3b and 4 Patients
10. Epilepsy Foundation Launches The "Epilepsy Innovation Seal Of Excellence" Recognizing Groundbreaking Product Candidates For People With Epilepsy
11. Ensil Canada Announces First Successful Test and Validation of Vastusys Line of Products in Ontario Laboratories
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/24/2016)... , June 24, 2016  Global Blood ... biopharmaceutical company developing novel therapeutics for the treatment ... today announced the closing of its previously announced ... stock, at the public offering price of $18.75 ... offering were offered by GBT. GBT estimates net ...
(Date:6/24/2016)... ALEXANDRIA, Va. , June 24, 2016 ... a set of recommendations that would allow ... information (HCEI) with entities that make formulary and coverage ... determine the "value" of new medicines. The ... that does not appear on the drug label, a ...
(Date:6/24/2016)... PUNE, India , June 24, 2016 ... "Pen Needles Market by Type (Standard Pen Needles, Safety ... 12mm), Therapy (Insulin, GLP-1, Growth Hormone), Mode of Purchase ... published by MarketsandMarkets, This report studies the market for ... is expected to reach USD 2.81 Billion by 2021 ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... Experts from the ... AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the Hynes Convention Center in ... topics including advance care planning, healthcare costs and patient and family engagement. , ...
(Date:6/25/2016)... ... 2016 , ... "With 30 hand-drawn hand gesture animations, FCPX users can easily ... of Pixel Film Studios. , ProHand Cartoon’s package transforms over 1,300 hand-drawn pictures ... . Simply select a ProHand generator and drag it above media or text in ...
(Date:6/25/2016)... ... June 25, 2016 , ... Dr. Calvin Johnson ... Recently, he has implemented orthobiologic procedures as a method for treating his patients. ... the first doctors to perform the treatment. Orthobiologics are substances that orthopaedic surgeons ...
(Date:6/24/2016)... , ... June 24, 2016 , ... A recent ... most people are unfamiliar with. The article goes on to state that individuals are ... many of these less common operations such as calf and cheek reduction. The Los ...
(Date:6/24/2016)... ... ... in a crisis. Her son James, eight, was out of control. Prone to extreme mood ... something upset him, he couldn’t control his emotions,” remembers Marcy. “If there was a ... children and say he was going to kill them. If we were driving on ...
Breaking Medicine News(10 mins):